神经保护
非西汀
医学
药理学
缺血
冲程(发动机)
组织纤溶酶原激活剂
谷胱甘肽
抗氧化剂
内科学
生物化学
类黄酮
化学
酶
机械工程
工程类
作者
Pamela Maher,Karmen F. Salgado,Justin A. Zivin,Paul A. Lapchak
出处
期刊:Brain Research
[Elsevier]
日期:2007-10-01
卷期号:1173: 117-125
被引量:123
标识
DOI:10.1016/j.brainres.2007.07.061
摘要
Despite the significant advances that have been made in understanding the pathophysiology of cerebral ischemia on the cellular and molecular level, only one drug, the thrombolytic tissue plasminogen activator (rt-PA), is approved by the FDA for use in patients with acute ischemic stroke. Therefore, there is a critical need for additional safe and effective treatments for stroke. In order to identify novel compounds that might be effective, we have developed a cell culture-based assay with death being an endpoint as a screening tool. We have performed an initial screening for potential neuroprotective drugs among a group of flavonoids by using the mouse hippocampal cell line, HT22, in combination with chemical ischemia. Further screens were provided by biochemical assays for ATP and glutathione, the major intracellular antioxidant, as well as for long-term induction of antioxidant proteins. Based upon the results of these screens, we tested the best flavonoid, fisetin, in the small clot embolism model of cerebral ischemia in rabbits. Fisetin significantly reduced the behavioral deficits following a stroke, providing proof of principle for this novel approach to identifying new compounds for the treatment of stroke.
科研通智能强力驱动
Strongly Powered by AbleSci AI